PharmacoEconomics & Outcomes News 784, p2 - 12 Aug 2017 Efforts to eliminate hepatitis gain momentum New WHO data reveal that efforts to eliminate hepatitis are gaining momentum in 28 countries which account for 70% of the global hepatitis burden. The data were published on World Hepatitis Day and shows that nearly all of the 28 countries have set up high-level national hepatitis elimination committees, with over half having dedicated funding allocated for hepatitis response. Over 86% of countries reviewed have established national hepatitis elimination targets, whilst over 70% have started the development of national plans to allow access to effective services for the prevention, diagnosis, treatment and care of hepatitis. WHO Director-General, Dr Tedros Adhanom Ghebreyesus, commented that "it is encouraging to see countries turning commitment into action to tackle hepatitis". However, WHO believes that countries need to accelerate their efforts and provide further investment in order for hepatitis elimination to become a reality. With the aim of increasing access to therapy, WHO has added the first generic version of a direct acting antiviral, sofosbuvir, to its list of pre-qualified hepatitis C medicines. A 3-month treatment course of this generic will cost $US260–$280 and can now be procured by the United Nations and financing agencies such as UNITAID. Additionally, WHO is promoting the prevention of hepatitis through injection safety via a new campaign titled "Get the Point – Make smart injection choices". The global hepatitis agenda will be further advanced during the World Hepatitis Summit to be held in Sao Paulo, Brazil, from 1–3 November 2017, which is themed "Implementing the Global health sector strategy on viral hepatitis: towards the elimination of hepatitis as a public health threat". WHO. Eliminate hepatitis: WHO. Internet Document : 27 Jul 2017. Available from: URL: http://www.who.int/mediacentre/news/releases/2017/eliminate- hepatitis/en/ 803262347 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera